Subscribe

Bliss GVS Pharma Limited (BLISSGVS.NS)

INR514.50 -6.60 (-1.27%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address 102, Hyde Park 400072
Mumbai, IN
CEO Shibroor Narsimha Kamath
Website blissgvs.com
IPO 2010-07-26
ISIN INE416D01022

Explore sections of this company profile

Also trades on Bombay Stock Exchange · BLISSGVS.BO (INR) National Stock Exchange of India · BLISSGVS.NS (INR)
Description

Established in 1984 and headquartered in Mumbai, India, Bliss GVS Pharma Limited specializes in the development, manufacturing, and distribution of a comprehensive array of pharmaceutical products. The company's pharmaceutical portfolio includes an extensive range of dosage forms, such as oral solids (tablets, capsules), various liquid and injectable preparations, topical applications (creams, gels), and advanced drug delivery systems like transdermal patches. Beyond conventional medicines, Bliss GVS also offers a diverse selection of other healthcare and personal care items, including balms, lotions, shampoos, and over-the-counter remedies. Their therapeutic focus is equally broad, encompassing solutions for anti-infectives, pain management, gastrointestinal issues, anti-malarials, dermatological conditions, nutritional support, and a wide variety of other wellness and hygiene products, including medicated and cosmetic soaps. The company actively engages in international exports, extending its market presence beyond India.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR514.50 -6.60 (-1.27%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.17
Float Shares
42.33M
Free Float %
40.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+1.96% +10.14% +14.59% +42.94% +77.65% +84.22% +139.65% +312.61% +171.91% +194.23% +637.75%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
514.50
DCF (Unlevered) 2.92 -99.4%
DCF (Levered) 108.44 -78.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Quality scores
Altman Z-Score
8.95
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +14.5% ★ Q1'26: +29.8% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +50.9% ★ Q1'26: +124.0% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +3.3% ★ Q1'26: +18.8% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +21.7% ★ Q1'26: +18.3% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +14.0% ★ Q1'26: +15.1% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +1.5% Q1'26: +2.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.09× ★ Q1'26: 0.10× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.95) × ERP
WACC = 99% × Ke + 1% × Kd (55.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 2.92 Current price: 514.50
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2013
actual 		Mar 2014
actual 		Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana. 		Mar 2031
1 Rev. Ana.
1 EPS Ana.
Revenue
3.97B
est: 3.45B (+15.1%)
3.47B
est: 3.42B (+1.4%)
4.07B
est: 3.39B (+20.1%)
5.47B
est: 3.54B (+54.6%)
8.00B
est: 3.75B (+113.2%)
3.64B
est: 9.60B (-62.1%)
8.86B
est: 8.66B (+2.3%)
6.82B
est: 10.06B (-32.2%)
5.69B
est: 11.47B (-50.4%)
8.10B
est: 3.39B (+138.9%)
3.54B
3.54B – 3.54B
+4.3% YoY
3.75B
3.75B – 3.75B
+6.1% YoY
9.60B
9.60B – 9.60B
+155.8% YoY
8.66B
8.66B – 8.66B
-9.8% YoY
10.06B
10.06B – 10.06B
+16.2% YoY
11.47B
11.47B – 11.47B
+14.0% YoY
EBITDA
1.11B
est: 591.16M (+87.3%)
739.72M
est: 575.20M (+28.6%)
1.24B
est: 581.65M (+112.7%)
1.79B
est: 606.91M (+194.5%)
1.12B
est: 643.74M (+73.7%)
816.67M
est: 3.20B (-74.5%)
1.95B
est: 1.49B (+31.4%)
1.49B
est: 3.84B (-61.2%)
1.27B
est: 1.97B (-35.5%)
1.27B
est: 602.31M (+110.3%)
628.47M
628.47M – 628.47M
+4.3% YoY
666.60M
666.60M – 666.60M
+6.1% YoY
1.71B
1.71B – 1.71B
+155.8% YoY
1.54B
1.54B – 1.54B
-9.8% YoY
1.79B
1.79B – 1.79B
+16.2% YoY
2.04B
2.04B – 2.04B
+14.0% YoY
EBIT
1.05B
est: 488.12M (+115.4%)
873.95M
est: 474.95M (+84.0%)
1.11B
est: 480.27M (+132.0%)
1.64B
est: 501.13M (+228.2%)
1.01B
est: 531.54M (+90.3%)
725.96M
est: 2.26B (-67.9%)
1.86B
est: 1.23B (+51.7%)
1.37B
est: 2.59B (-47.2%)
1.10B
est: 1.62B (-32.5%)
972.66M
est: 496.98M (+95.7%)
518.57M
518.57M – 518.57M
+4.3% YoY
550.03M
550.03M – 550.03M
+6.1% YoY
1.41B
1.41B – 1.41B
+155.8% YoY
1.27B
1.27B – 1.27B
-9.8% YoY
1.47B
1.47B – 1.47B
+16.2% YoY
1.68B
1.68B – 1.68B
+14.0% YoY
Net Income
577.20M
est: 692.44M (-16.6%)
409.92M
est: 647.92M (-36.7%)
599.10M
est: 713.63M (-16.0%)
824.83M
est: 669.09M (+23.3%)
856.11M
est: 741.20M (+15.5%)
587.85M
est: 1.05B (-44.1%)
1.24B
est: 1.39B (-11.1%)
972.65M
est: 2.12B (-54.1%)
684.91M
est: 1.69B (-59.4%)
842.99M
est: 724.20M (+16.4%)
679.00M
679.00M – 679.00M
-6.2% YoY
752.18M
752.18M – 752.18M
+10.8% YoY
1.07B
1.07B – 1.07B
+41.9% YoY
1.41B
1.41B – 1.41B
+32.3% YoY
1.51B
1.51B – 1.51B
+6.7% YoY
1.71B
1.71B – 1.71B
+13.7% YoY
SGA
658.94M
est: 296.12M (+122.5%)
828.43M
est: 288.13M (+187.5%)
763.87M
est: 291.36M (+162.2%)
892.90M
est: 304.01M (+193.7%)
623.46M
est: 322.46M (+93.3%)
196.52M
est: 1.24B (-84.2%)
276.88M
est: 744.16M (-62.8%)
271.81M
est: 1.03B (-73.6%)
279.21M
est: 985.74M (-71.7%)
1.50B
est: 258.07M (+480.4%)
269.28M
269.28M – 269.28M
+4.3% YoY
285.62M
285.62M – 285.62M
+6.1% YoY
730.61M
730.61M – 730.61M
+155.8% YoY
659.14M
659.14M – 659.14M
-9.8% YoY
765.89M
765.89M – 765.89M
+16.2% YoY
873.12M
873.12M – 873.12M
+14.0% YoY
EPS
5.60
est: 6.53 (-14.2%)
3.97
est: 6.20 (-36.0%)
5.81
est: 6.73 (-13.7%)
8.00
est: 6.31 (+26.8%)
7.95
est: 6.99 (+13.7%)
5.70
est: 9.92 (-42.5%)
11.99
est: 13.12 (-8.6%)
9.43
est: 14.00 (-32.6%)
6.64
est: 15.92 (-58.3%)
8.02
est: 6.73 (+19.2%)
6.31
6.31 – 6.31
-6.2% YoY
6.99
6.99 – 6.99
+10.8% YoY
9.92
9.92 – 9.92
+41.9% YoY
13.12
13.12 – 13.12
+32.3% YoY
14.00
14.00 – 14.00
+6.7% YoY
15.92
15.92 – 15.92
+13.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-21 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-20 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-19 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-18 C- 1/5 3/5 1/5 1/5 1/5 2/5 1/5
2026-05-15 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-14 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-13 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-12 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-11 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-08 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-07 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-06 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-05 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-05-04 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-30 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-29 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-28 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-27 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-24 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-23 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-22 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-21 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-20 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-17 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5
2026-04-16 C 2/5 3/5 1/5 1/5 1/5 3/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
185.41M
OE per share TTM
1.75
Owner's Yield
0.57%
Maintenance CapEx ratio
22.33%
Maint CapEx / Avg PPE
40.3%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
2.43M
Shares Outstanding
105.79M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Aditi H. Bhatt Compliance Officer, Company Secretary & Nodal Officer — female
Deepak Sawant Chief Financial Officer — male
Prashant Churi Vice President of Technical Operations — male
Shibroor Narsimha Kamath Chief Executive Officer — male
Shreekrushna Joshi Head of Legal — male
Sourya Das Associate Vice President — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic